ONWARD Medical sees commercial success with ARC-EX System sales and positive clinical study results

From GlobeNewswire: 2025-06-17 01:30:00

ONWARD Medical N.V. announces Q1 2025 update, achieving commercial traction with ten ARC-EX® System sales in the US. Technology milestones include successful BCI implants and first human implant of ARC-IM Lumbar Lead. Pathfinder2 study results show sustained ARC-EX Therapy benefits. Financially, the Company reports revenue of EUR 0.4M and net cash of EUR 50.5M.

CEO Dave Marver expresses confidence in ONWARD’s ability to deliver breakthrough therapies. The Company met its Q1 objective for the limited US launch of the ARC-EX System, selling ten systems. Positive feedback and strong demand indicate a promising outlook for sales and growth in 2025. Access to US government procurement platforms secured.

ONWARD advances ARC-IM System with first human implant of ARC-IM Lumbar Lead. Grants support clinical studies for Parkinson’s disease. Company prepares for Empower BP pivotal study pending FDA approval. ARC-BCI technology showcases successful implants and gains coverage on CBS 60 Minutes.

Scientific leadership highlighted with positive Pathfinder2 study results published in Neuromodulation journal. Participants in the one-year trial experienced significant functional improvements with ARC-EX Therapy. Financially, ONWARD reports revenue of EUR 0.4M and net cash of EUR 50.5M. A sponsored ADR program was established for US investors.

Strong early demand for the ARC-EX System propels ONWARD towards meeting 1H sales target. FDA clearance and CE Mark authorization expected. Plans for global pivotal study of ARC-IM System and additional implants in SCI and Parkinson’s disease. Webcast hosted by CEO Dave Marver available for further information.



Read more at GlobeNewswire:: ONWARD Medical Builds Commercial Momentum for the ARC-EX